Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 36

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 36
---
                                                                     | 109,082 |     |                                                                       |   9,917 |     |                           |  6.60 |     | 04/29/2031             |     |                                                                |        |     |                                                                      |         |
|                    |     | 05/12/2022(2) |     | 03/25/2022                |     |                                                                     |  45,375 |     |                                                                       |  20,625 |     |                           | 17.28 |     | 05/11/2032             |     |                                                                |        |     |                                                                      |         |
|                    |     | 02/15/2023(2) |     | 01/01/2023                |     |                                                                     |  33,996 |     |                                                                       |  36,954 |     |                           | 14.29 |     | 02/14/2033             |     |                                                                |        |     |                                                                      |         |
|                    |     | 03/15/2024(2) |     | 01/01/2024                |     |                                                                     |  13,750 |     |                                                                       |  46,250 |     |                           |  3.00 |     | 3/14/2034              |     |                                                                | 30,000 |     |                                                                      |  41,400 |

(1) All of the option awards granted prior to March 24, 2022 were made under the 2017 Plan and all grants made subsequent to March 24, 2022 were made under our 2022 Plan. (2) These options vest in respect of 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date subject to the executive’s continuous employment. The option is subject to the vesting acceleration provision described above under “—Potential Payments and Benefits upon Termination or Change in Control.” (3) Except as noted in footnote (5) below, these RSUs vest in respect of 25% of the underlying shares on each anniversary of the vesting commencement date subject to the executive’s continuous employment. The RSUs are subject to the vesting acceleration provision described above under “—Potential Payments and Benefits upon Termination or Change in Control.”

<div align='center'>19</div>

(4) These options vest in respect of 25% of the underlying shares on the first anniversary of the vesting commencement